Fate Therapeutics
FATE
1,43 €
Share price
1.82%
Change (1 day)
-60.06%
Change (1 year)
Categories
Earnings for Fate Therapeutics (FATE)
Earnings in 2025 (TTM): -€0.18 Billion
According to Fate Therapeutics 's latest financial reports the company's current earnings are €13.33 Million. In 2024 the company made an earning of -€0.18 Billion a decrease over its 2023 earnings that were of -€0.17 Billion. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Fate Therapeutics from 2013 to 2025
Annual earnings
| Year | Earnings | Change |
|---|---|---|
2025 (TTM)  | -€0.18 Billion | 0.67% |
| 2024 | -€0.18 Billion | 2.64% |
| 2023 | -€0.17 Billion | -38.22% |
| 2022 | -€0.27 Billion | 45.36% |
| 2021 | -€0.19 Billion | 43.54% |
| 2020 | -€0.13 Billion | 53.32% |
| 2019 | -€84.36 Million | 48.53% |
| 2018 | -€56.8 Million | 55.7% |
| 2017 | -€36.48 Million | 30.98% |
| 2016 | -€27.86 Million | 14.59% |
| 2015 | -€24.31 Million | 9.62% |
| 2014 | -€22.17 Million | 14.83% |
| 2013 | -€19.31 Million |
Earnings for similar companies or competitors
| Company | Earnings | Earnings differencediff. | Country |
|---|---|---|---|
 Sarepta Therapeutics
SRPT | -€0.15 Billion | -11.61% | 🇺🇸 USA |
 Becton Dickinson BDX | €1.47 B | -1,006.05% | 🇺🇸 USA |
 PTC Therapeutics
PTCT | €0.57 B | -450.69% | 🇺🇸 USA |
 Avidity Biosciences RNA | -€0.33 Billion | 98.77% | 🇺🇸 USA |
 Neurocrine Biosciences
NBIX | €0.46 B | -385.87% | 🇺🇸 USA |